Ionis Pharmaceuticals Inc
NASDAQ:IONS

Watchlist Manager
Ionis Pharmaceuticals Inc Logo
Ionis Pharmaceuticals Inc
NASDAQ:IONS
Watchlist
Price: 37.25 USD -1.4% Market Closed
Market Cap: 5.9B USD
Have any thoughts about
Ionis Pharmaceuticals Inc?
Write Note

Ionis Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ionis Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Ionis Pharmaceuticals Inc
NASDAQ:IONS
Revenue
$803.1m
CAGR 3-Years
7%
CAGR 5-Years
0%
CAGR 10-Years
17%
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%

Ionis Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
Ionis Pharmaceuticals Inc

Not Available

Breakdown by Segments
Ionis Pharmaceuticals Inc

Total Revenue: 787.6m USD
100%
Research And Development Revenue: 479.1m USD
60.8%
Collaborative Agreement Revenue: 352.7m USD
44.8%
Commercial: 308.6m USD
39.2%
Spinraza Royalties: 240.4m USD
30.5%
Other Commercial: 68.2m USD
8.7%
Product: 34.9m USD
4.4%
Licensing And Other Royalties: 33.3m USD
4.2%
Show More
Show Less

See Also

What is Ionis Pharmaceuticals Inc's Revenue?
Revenue
803.1m USD

Based on the financial report for Sep 30, 2024, Ionis Pharmaceuticals Inc's Revenue amounts to 803.1m USD.

What is Ionis Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
17%

Over the last year, the Revenue growth was 31%. The average annual Revenue growth rates for Ionis Pharmaceuticals Inc have been 7% over the past three years , and 17% over the past ten years .

Back to Top